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1. Introduction 
Iran has a long history of political and economic 
relations with Russia. From the ages of trading Rus-
sian fur for Iranian fine saffron back in Safavid Dyn-
asty (Barazesh, 2012, p. 283), both Iranians and Rus-
sians have enjoyed the vicinity of each other trading 
goods for Trade. Being able to trade through both sea 
and land (naval fleet crossing the Caspian Sea from 
Anzali port to Astrakhan port in Russia and routes 
through Caucasus area, linking the nations by land), 
both parties have discovered the economical mutual 
benefit of trading with each other, long time ago.  
While the two nations appear to have strong po-
litical ties, talking about trading, we’re not witnessing 
that kind of coherence in this regard. As of the year 
2018, things are quite the same; indeed, the shape of 
this relation has changed in many ways. According to 
Trade Map, the latest statistics available, which be-
long to the year 2018, suggest that a heavy trade im-
balance exists between the two countries. In 2018, 
Russia has exported a nearly 1.2$ billion worth of 
products to the Islamic Republic of Iran, while the 
vice versa figures are around 280$ million. The num-
bers have dropped for Russia compared to the previ-
ous year, in which about 1.3$ billions worth of prod-
ucts was imported by Iran and the same has happened 
for Iran with about 285$ million worth of products 
exported to the Russian Federation in 2017; this indi-
cates an overall decrease in the bilateral trade between 
the two countries. 
 
One of the solutions to improve the trade flows 
between two countries is expansion of non-oil export-
ing of Iran to Russia, particularly pharmaceutical 
products in which Iran has a big and significant pro-
duction potential. Generally, pharmaceutical products 
are classified under code 30 and include groups 3001 
to 3006 in Harmonized System (HS) of commodities 
classification.  
In regards to pharmaceutical products, Russia is 
the fifth-largest importer of pharmaceuticals from 
Iran, importing $ 18.8 million worth of medicinal 
products from Iran in 2017, down to less than $ 7 mil-
lion the following year. Exports of Iranian pharmaceu-
tical products to Russia have practically boomed since 
2012, rising from $ 51,000 in 2011 to over $ 12 mil-
lion in 2012. 
Table 1 
Total Export of Commodity Group Code 3004  
from Iran to Russia, USD 
Export value Year Export value Year 
0 2010 0 2001 
51,000 2011 43,000 2002 
12,353,000 2012 86,000 2003 
15,322,000 2013 110,000 2004 
28,561,000 2014 79,000 2005 
518,000 2015 90,000 2006 
17,680,000 2016 0 2007 
18,824,000 2017 5,000 2008 
6,867,000 2018 0 2009 
Source: Authors’ compilation from Trademap.org 
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According to the data provided by ICCIMA
1
 and 
comparing it with Trademap statistics, commodities 
under the code 3004 are the main export of Iranian 
pharmaceutical products to Russia. If we take a look at 
Iran's total export of pharmaceuticals and examine six 
groups of commodities in this collection, we will find 
out why. Since 2001, the major export of Iranian 
pharmaceutical products has been the Commodity 
Code 3004. Then the commodity group code 3002 
with an export volume averaging one-third to one-
quarter of commodity group 3004. Other commodity 
groups also account for a very small share of the ex-
port of Iranian pharmaceutical products compared to 
the two already-mentioned commodity groups, with 
exports of Group 3003 products reaching to only $ 10 
million over 7 years out of the 18 studied years. Other 
commodity groups have not yet reached $ 1 million 
(The only exception is Group 3005 in 2017). 
In the case of the Commodity Group 3006 (also 
known as specialized pharmaceutical products (OEC 
website)), it can be deduced that the products of this 
subgroup, due to the need of high technology indus-
tries for their production, along with their very high 
hygiene requirements, these type of products (since 
they are in direct contact with internal organs and may 
cause irreparable damage), are not a part of Iran's 
pharmaceutical exports to the Russian market, and 
with the exception of a minor case reported by the 
Iranian Customs in 2010, Iran has not made any sig-
nificant exports to Russia in this regard. 
Iran's failure to expand the export of commodity 
group No. 3002 to Russia may be due to their high 
level of health sensitivity. Also, in the field of antise-
ra, and other blood derivatives and immunogenic 
products, vaccines, toxins and the cultivation of or-
ganisms can also be subject to technical restrictions on 
their domestic production, as well as the lack of the 
necessary certificates for importing them to the Rus-
sian market. 
According to the data provided by Iran Customs, 
only in the years 2001 and 2008, a limited amount of 
products in the 3003 group were exported to Russia, 
indicating the inattention of Iranian pharmaceutical 
companies and exporters to this category of products. 
Iran also has not had significant exports to Russia in 
the field of Commodity Group 3001, and for the past 
18 years, Iran Customs has recorded near-zero statis-
tics for this group. 
According to the importance of non-oil export 
expansion of Iran, leading to a less dependency to oil 
exporting revenues, and the fantastic market of Rus-
sia, this paper seeks to analyze the potentials of in-
creasing the exports of pharmaceutical products as 
non-oil and non-sanctioned products, which are of 
great importance to Iran, and identifies untapped po-
tentials as well as the various obstacles in this trade. 
                                                          
1
 The Iran Chamber of Commerce, Industries, Mines and 
Agriculture. 
Despite earlier studies (e.g. see Rasoulinezhad (2016), 
Haghayegh and Hassangholipoor (2017),Koolaee and 
Abedi (2018); Karami et al. (2019)) about Iran-Russia 
trade flows, there has not been any serious academic 
attempt focusing on exporting pharmaceutical prod-
ucts to the vast market of Russia. Hence, it clarifies 
our research novelty and shows the literature gap that 
will be filled in by our research. 
Table 2 
Total Export of Commodity Group Code 3003  
from Iran to Russia, USD 
Export value Year Export value Year 
0 2010 47,000 2001 
0 2011 0 2002 
0 2012 0 2003 
0 2013 0 2004 
0 2014 0 2005 
0 2015 0 2006 
0 2016 0 2007 
0 2017 490,000 2008 
0 2018 0 2009 
Source: Authors’ compilation from Trademap.org 
 
The rest of the paper is structured as follows: 
Section 2 discusses the existing literature review. Next 
section explains research methodology. Section 4 rep-
resents empirical findings while the last Section con-
cludes the paper with some policy implications. 
2. Literature Review 
The related existing literature can be divided into 
three stands. First one concentrates on the characteristics 
of pharmaceutical commodities trade in the world. Se-
cond strand focuses on pharmaceutical trade in Iran and 
Russia, while the third strand of literature includes the 
studies about trade patterns between Iran and Russia. 
The first strand of literature includes studies 
about the specifications of pharmaceutical commodi-
ties trade in different countries. Micklitz (1988) ar-
gued about possibilities of the European nations to 
participate in the WHO regulations. He concluded that 
the European pharmaceutical industry needs to adopt 
with the WHO principles, particularly in order to ex-
port of pharmaceutical commodities to third world 
countries. Chaudhry and Dacin (1997) studied the 
pharmaceutical industry in the European Union. The 
results revealed that due to the changing Trade envi-
ronment in the EU, the pharmaceutical industry of this 
trade bloc is trying to expand their market to other 
regions and countries. Palumbo et al. (2007) focused 
on policy implications of drug importation to the US. 
The research highlighted that policy makers in the US 
are under heavy pressure to address the high cost of 
branded drugs in this country. Bert (2008) investigated 
parallel trade of pharmaceuticals (PPT) over 2006–
2007. He found out that pharmaceuticals trade in de-
veloped nations is a ubiquitous phenomenon and also 
the global growth of health care expenditures has im-
proved the flows of pharmaceutical trade among coun-
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tries. Chadha (2009) focused on neo-technology theo-
ries of trade in Indian pharmaceuticals’ trade. The 
findings showed that technology has a positive impact 
on exports. Settanni et al. (2017) reviewed pharmaceu-
tical supply chain models. They found out that pro-
duction level of these commodities is important in the 
supply chain rather than patient consumption pattern 
and healthcare outcomes. Garattini and Padula (2018) 
investigated competition in pharmaceuticals during 
the life cycle of a drug based on the European Union 
regulations. They expressed that a comprehensive 
regulatory system to favor more fairly competition for 
merit goods like drugs.  
The second strand of literature concentrates on 
pharmaceutical commodities trade in Iran or Russia 
with the world. In regards to Iran, Zargarzadeh et al. 
(2008) used a cross-sectional study to analyze self-
medication in Isfahan. The major results proved that 
because of high self-medication of Iranian people, the 
consumption of pharmaceutical commodities is high 
in this country and it would be a big challenge for 
Iran’s pharmaceutical exporting to other countries. 
Mahmoudzadeh et al. (2012) investigated the competi-
tion of Iran in drug export over the period of 2002–
2010. The findings revealed that Iranian drug export is 
on an upward trend and this country has a big poten-
tial to expand its exporting line of pharmaceutical 
goods to other nations. Nessabian and Gholamoseini 
(2012) tried to compare the Iran’s medical plants ex-
porting comparative advantage using the Revealed 
Symmetric Comparative Advantage. They proved that 
despite the existence of comparative advantage of Iran 
in export of medicinal plants, its export competitive-
ness trend is declining over time. Shahbazi and Asadi 
(2014) studied the relationship between exchange rate 
and imports of medicines in Iran over 1977–2010. 
They found out that due to the absence of pharmaceu-
tical industries’ protections against sharp increase in 
exchange rate the import volume of pharmaceutical 
products of Iran has decreased significantly. 
Emamgholipour and Agheli (2019) studied the struc-
ture of pharmaceutical industry in this country over 
1992–2016. They found out pharmaceutical produc-
ers, importers and distributers in Iran’s pharmaceutical 
market have made a monopolistic competition market. 
However, importers play a significant role in drug’s 
prices in Iran. In the case of Russia, Tannoury and 
Attieh (2017) investigated the pharmaceutical markets 
under the effects of Russia and other BRICS mem-
bers. They found out that pharmaceutical companies 
have a unique attention to the market of BRICS be-
cause of fast rise in the incidence of non communica-
ble diseases in these emerging countries. Holownia-
Voloskova et al. (2018) reviewed drug policy in Rus-
sian healthcare system. The major results showed that 
the healthcare system in this country is complicated 
and requires development to carry out import substitu-
tion policy efficiently. 
Finally, the third strand of literature contains 
studies about bilateral trade pattern between Iran and 
Russia. Rasoulinezhad (2016) tried to find the effects 
of sanctions and oil price shocks on Iran-Russia bilat-
eral trade over the period of 1994–2013. He found out 
the negative relationship between financial, non-
financial sanctions and oil price shocks with the Iran-
Russia trade. Haghayegh and Hassangholipoor (2017) 
argued that bilateral trade between Iran and Russia can 
be improved by implication of non-oil trading strategy 
which is vital for both countries due to the regional 
tensions and economic pressures under sanctions. 
Koolaee and Abedi (2018) reviewed Iran-Russia bilat-
eral trade relations since the USSR collapse. They 
highlighted that political interests of Russia strongly 
impacts on Iran-Russia trade flows, while Iranian ex-
porters have been trying to have a larger market share 
in Russia. Karami et al. (2019) studied the characteris-
tics of trade pattern between these two countries. The 
results proved that under the western sanctions these 
two countries have temporary economic and trade tie 
to combat negative effects of sanctions. 
Overall, the existing literature proves that bilat-
eral trade between Iran and Russia is important and 
needs to be improved. Furthermore, there has not been 
an academic work focusing on pharmaceutical com-
modities export of Iran to Russian market. Therefore, 
this literature gap will be filled in by our research. 
3. Research Methodology 
The aim of this paper is to find out export poten-
tial and comparative advantage of Iran to deal in trade 
with Russia with pharmaceutical products. To this 
end, we carry out three popular indexes, namely Co-
sine index, NRCA (Normalized Revealed Compara-
tive Advantage) index and Trade Plan index for the 
data of pharmaceutical trade over the period of 2001–
2018. The applied indexes are explained as follows: 
Cosine Index: 
This index proposed by Allen (1956: 135) is an 
appropriate measure to evaluate the complementarity 
of trade between countries. The cosine index that rep-
resents the angle between the exports of pharmaceuti-
cal commodities of Iran (country i) with the imports of 
pharmaceutical commodities of Russia (country j) can 
be estimated by the following equation: 
      
     
        
        
        
          
 
   
 
K = 1,2,3,…,n–1,n. 
According to the above-mentioned formula, if the 
export commodity composition of country i is identi-
cal to country j, it shows complete completion, mean-
ing the export patterns of the exporting and importing 
countries are exactly the same; and if for all k, Eik or 
Mik or both are zero, it is clear that trading from coun-
try i to country j is not possible, and the vectors of Ei 
and Mi are perpendicular, thus Cosij = 0 and there is 
no level of trade completion. Therefore, the cosine 
between two vectors can be placed between two criti-
cal values of zero and one. The similarity standard 
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(cosine) only provides the expected intensity of cross-
border trade flows from the exporting country i to the 
importing country j based on existing trade patterns. 
This standard does not recognize the trade potential 
assessment. In other words, the trade of the two coun-
tries may be quite similar, although it is unclear 
whether they actually did trade with each other or not. 
In addition, when the similarities are compared, nei-
ther the reason for this situation nor the behavior that 
may mutually occur is explained (Rahmani & Abedin, 
2008: 159–158). 
The Normalized Revealed Comparative Ad-
vantage Index 
The NRCA index measures the degree of devia-
tion of a country’s actual export from its comparative-
advantage-neutral level in terms of its relative scale 
with respect to the world export market and thus, pro-
vides a proper indication of the underlying compara-
tive advantage. 
The key to the derivation of the NRCA index is the 
comparative-advantage-neutral level (point). The exist-
ing RCA measures indeed have a consensus on this situ-
ation (Yu et al. 2008: 267–268; Bojnec and Ferto, 2014: 
6156). In the situation of a comparative-advantage-
neutral, country i’s export of commodity j (or E˄ij), 
would equal Ei Ej /E. Country i’s actual export of com-
modity j in the real terms, Eij, would normally differ 












Normalizing ΔEij by the world export market 
(E), we obtain the NRCA index as follows; 
NRCA = Δ Eij / E = Eij / E – Ej Ei / E E. 
Trade Plan Index 
UNCTAD (United Nations Conference on Trade 
and Development) International Trade Center uses the 
Trade Plan to analyze the exporting of different com-
modity groups. A Trade plan compares export growth 
with global demand growth. More precisely, the 
growth of export of product i by a country (δij) is 
compared with the growth of world imports of the 
same product (ri) and total growth of the whole world 
imports (r). 
A Trade plan is divided into four different quar-
ters, according to which, the exported products are 
categorized into the groups of winners (2 groups) or 
losers (2 groups) based on their placement in the 
growing markets or in declining markets. 
The characteristics of each quadrant are as fol-
lows. 
4. Empirical findings 
In this section, the empirical findings of estimat-
ing the Cosine index, NRCA index and Trade Plan 
index are represented as follows: 
Cosine Index Results 
According to the results of the Cosine index for 
Iran’s pharmaceutical exports and pharmaceutical 
Russia’s imports, there is a high degree of similarity 
between these two nations in 3 years among the period 
of 2001 to 2018. It has a maximum of 0.8511 and 
0.8710 in 2001 and 2018, respectively, while its min-
imum were in 2017. The main reasons of its highest 
amount in 2001 and 2018 is the visiting of Russia by 
Iranian President Mr. Khatami in 2001 which led to 
expand trade ties in non-oil commodities such as 
pharmaceutical ones. In addition, US withdrawal from 
JCPOA (Joint Comprehensive Plan of Actions) and 
returning sanctions against Iran caused the trade inte-
gration of this country with Russia to lower the nega-
tive effects of the imposed sanctions (Sajedi and 
Sajedi (2019: 141) expressed that the US exit from 
JCPOA has brought various negative signals for Irani-
an macroeconomic variables). 
Based on the results of the Cosine index calcula-
tion, it can be concluded that the exports of pharmaceu-
tical products by Iran with the same imported products 
by Russia have an average level of similarity which 
provides a good opportunity for exports expansion. 
NRCA Index Results 
According to the normalized revealed compara-
tive advantage index calculations (Fig 1) for Iran’s 
pharmaceutical exports, the country has a good rela-
tive advantage in exporting the commodity group 
 
Table 3 
Features of the quarters in Trade Plan Index (BPI) 
δij ri r Winners in growing markets 1
st
 quarter 
δij ri , ri r Losers in growing markets 2
nd
 quarter 
δij ri r Losers in declining markets 3
rd
 quarter 
δij ri , ri  r Winners in declining markets 4
th
 quarter 
Source: Authors’ compilation 
 
Table 4 
Cosine Index results 
2001 2002 2003 2004 2005 2006 2007 2008 2009 
0.8511 0.7175 0.6774 0.6207 0.5593 0.5519 0.5507 0.5537 0.5492 
2010 2011 2012 2013 2014 2015 2016 2017 2018 
0.5454 0.5457 0.5528 0.5464 0.5470 0.5484 0.5559 0.5420 0.8710 
Source: Authors’ calculation based on raw data of Trademap 
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3004 and has been in the range of 0.7 to 0.9 in this re-
gard since 2005. But the actual amount of exports of 
this commodity group to Russia, except in 2014, has 
been less than $ 2 million a year in all the years studied. 
The sharp drop in the exports of these products to Rus-
sia in 2018 is the result of the ban on export of pharma-
ceutical products from Iran that was implemented on 
that year. According to the calculations of this index, 
Iran does not have a significant advantage in exporting 
other pharmaceutical commodity groups and the trade 
statistics will confirm this statement as well. 
Trade Plan Index Results 
Based on the results of Trade Plan Index, report-
ed in Table 4, Iran is placed in the 1st quarter (winners 
in the growing markets) in three commodity groups 
(3002, 3004 and 3006), and the export growth of these 
commodity groups has been higher than the global 
growth in imports for the same commodities; These 
commodities have been exported to markets with an 
increasing demand for imports. Iran has been placed in 
the second quarter (losers in growing markets) in the 
table of Trade plan for exporting commodity groups 
3001 and 3003, meaning that the export growth of 
these two commodity groups was lower than the glob-
al growth of importing these commodities and these 
commodity groups have been exported to markets 
where there is an increasing import demand for these 
commodities. The index puts Iran's export of com-
modity group 3005 in the fourth quarter of the Trade 
plan (winners in declining markets), which means 
Iran's export growth regarding this commodity group 
is higher than that of its global import growth, but the 
exports were made to the markets, where the import 
demand is falling. 
 
Table 5 
Trade plan Index results 
δij ri r 3002-3004-3006 1st quarter 
δij ri , ri r 3001-3003 2nd quarter 
δij ri r  3rd quarter 
δij ri , ri  r 3005 4th quarter 
Source: Authors’ calculation based on raw data of Trademap 
 
5. Discussion  
The empirical findings revealed that Iran could not 
use all the existing potential of Russian pharmaceutical 
market over the last decades. One of the main obstacles 
of exporting of pharmaceutical products to the vast 
market of Russia is “domestic Policies”. Domestic poli-
cies may occasionally lead to negative growth in ex-
ports of pharmaceuticals, such as the ban set on the 
exports of pharmaceutical products introduced in 2018 
following the Iranian government's attempts to stop the 
sharp value loss of Iranian currency (Rial), resulting in 
a heavy decrease of country’s export of pharmaceutical 
products to Russia. Another main reason is 
exportrequirements and documentations. The long pro-
cess of obtaining export licenses for pharmaceuticals 
and the load of restrictions set on exporters as a result 
of export bans have made a direct negative effect on 
Iran's pharmaceutical exports to Russia. 
Drug Manufacturing Issues is another limitation to 
expand pharmaceutical exports from Iran to Russia. 
Lack of effective government support for pharmacists 
to expand their drug exports and a shortage of unpro-
cessed materials for pharmaceutical production, due to 
low value of national currency, has reduced the produc-
tion ability and export capacity of Iranian pharmacists 
 
 
Fig 1. NRCA Index results 
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and exporters. Moreover, absence of industry-university 
collaboration may be considered as another reason of 
limitation to expand pharmaceutical exports from Iran 
to Russia. Expanding knowledge-based companies and 
linking the country's research centers to the manufactur-
ing sectors of the country's pharmaceutical industry will 
expand Iran's commodity exports and increase its com-
peting abilities to actively participate in the Russian 
pharmaceutical imports market. Economic Crisis is 
another export limitation for Iran to Russia. The deteri-
oration of the economic situation in Iran, especially 
since 2018, following the unprecedented fall of the na-
tional currency value, has deprived Iranian manufactur-
ers from the necessary stability for a cost-effective pro-
duction of pharmaceuticals and caused severe price 
volatility regarding domestic and foreign sales. This has 
made a detrimental effect on the status of Iranian phar-
maceutical exports to Russia.  
The above mentioned factors can be considered as 
internal ones. Besides, there are some regional factors 
limiting pharmaceutical exporting of Iran to Russia. 
One of the main regional factors is political tensions. 
Political relations and tensions between countries in the 
region occasionally lead to the disruption of transit of 
goods and services, borders closings, imposing heavy 
tariffs or implementing non-tariff barriers (requiring 
various certificates, permissions and etc.) or a direct ban 
on the import of goods from a specific country may 
prevent exports from Iran to Russia. Banking and Pay-
ment Issues are other regional factors influencing on 
pharmaceutical exporting volume from Iran to Russia. 
The absence of a sustainable connection of the Iranian 
banking network to the Russian banking system via the 
SWIFT network due to the western sanctions, as well as 
the inadequate infrastructures is another a barrier. An 
example is Mir Trade Bank's defective activities and its 
failure to obtain the desired financial results is the proof 
to these issues. 
International Factors can play a limiting role to 
export pharmaceutical products from Iran to Russia. 
Sanctions by western countries that restrict Iran's ac-
cess to international markets and prevent it from con-
ducting financial transactions through international 
banking system with its trading partners (in this case 
Russia). Iranian manufacturers are prohibited from 
exchanging knowledge, information and services with 
international scientific institutions and manufacturers 
of advanced pharmaceutical products. In addition, 
global competition is another international factor, ex-
pressing that export expansion of Iranian pharmaceu-
tical products to the Russian market will certainly face 
a heavy competition with top global manufacturers 
and exporters of these products. For example, Germa-
ny exported more than $ 2.2 billion to Russia in 2018, 
compared with the total $ 105 million pharmaceutical 
exports of Iran in that year, the huge difference be-
tween the top global exporters and the Iranian compa- 
 
 
nies. According to 2018 statistics, Iran has been 
ranked 45th among the exporters of pharmaceuticals 
to Russia, and this country should definitely be able to 
produce quality pharmaceuticals approved by the rele-
vant Russian authorities and at affordable prices in 
order to increase its amount of exports. 
6. Concluding remarks 
This study sought to investigate the characteris-
tics of pharmaceutical exporting of Iran to Russia over 
2001 to 2018. To this end, the authors employed three 
trade indexes of Cosine index, NRCA and Trade Plan 
Index (BPI) to evaluate the potential of Iran in export-
ing pharmaceutical commodities (HS codes of 3001 to 
3006). According to the results of the calculations of 
Cosine index, in 3 years of the total studied years, 
there is a high degree of similarity between Russian 
pharmaceutical imports and Iran’s pharmaceutical 
exports and in 2 of those years, there is a high degree 
of similarity. According to the results of the Cosine 
Index, it can be deduced that the exported pharmaceu-
tical goods by Iran have continuously been moderately 
similar to the Russian imported pharmaceutical goods. 
Furthermore, the results of the calculations of Normal-
ized Comparative Advantage Index revealed that Iran 
has had an advantage in the range of 0.7 to 0.9 (with 
number 1 as the maximum and 0 as the minimum) in 
exporting pharmaceutical goods to Russia from 2005 
to 2017, which can be counted as a very high ad-
vantage. This advantage, however, has sharply de-
clined in 2018, as a direct result of Iran's ban on drug 
exports during that year. Iran has the most relative 
advantage in exporting commodity groups 3004 and 
3002 to Russia, respectively. According to statistics, 
this advantage has not been practically used by Iranian 
exporters. In addition, the major findings of the calcula-
tions of Trade Plan Index indicated that Iran is placed in 
the first quarter of the Trade plan for three commodity 
groups (3002, 3004 and 3006) among the winners in the 
growing markets. Iran is placed in the second quarter of 
the table (losers in the growing markets) regarding the 
export of commodity groups 3001 and 3003 and the 
results of this index for the commodity group 3005 put 
Iran in the fourth quarter of the Trade plans (winners in 
the declining markets). Based on the findings, it can be 
concluded that Iran faces a vast number of obstacles 
(i.e. internal, regional and international factors) when it 
comes to export expansion of its pharmaceutical prod-
ucts to the Russian market. 
All in all, the authors would like to declare that 
this research suffers from different limitations like 
lack of available data of pharmaceutical exporting 
companies in Iran. Therefore, we recommend the fu-
ture studies to investigate the opinions of pharmaceu-
tical exporting companies about the trade obstacles 
between Iran and Russia. Furthermore, using other 
indexes such as Trade Intensity and Balassa index is 
suggested to have more reliable results. 
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ЭКСПОРТ ИРАНСКОЙ ФАРМАЦЕВТИЧЕСКОЙ ПРОДУКЦИИ  
НА РОССИЙСКИЙ РЫНОК: ПОТЕНЦИАЛЫ И БАРЬЕРЫ 
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Фармацевтический рынок – одна из важнейших отраслей мировой торговли. Расширение 
ненефтяного экспорта и уход от монопродуктовой экономики и связанных с ней проблем (высо-
кая волатильность на рынке нефти и, как следствие, доходов страны, а также вопрос о западных 
санкциях в отношении продажи нефти Ирана) сделали неизбежно для Ирана расширение экс-
порта фармацевтической продукции. Между тем, Российская Федерация по историческим при-
чинам имеет высокий потенциал стать местом назначения иранской фармацевтической продук-
ции из-за географической близости двух стран и возможности прямых поставок товаров в Рос-
сию через Каспийское море. Россия считается крупным рынком-потребителем с населением 145 
миллионов человек и большим объемом импорта фармацевтической продукции (более 10,5 мил-
лиардов долларов в 2018 году). В статье анализируется фармацевтический экспортный потенци-
ал Ирана в Российскую Федерацию с использованием показателей «Индекс выявленных сравни-
тельных преимуществ», «Индекс косинуса» и «Индекс торгового плана». Результаты указывают 
на высокий потенциал иранских фармацевтических продуктов для экспорта на российский по-
требительский рынок, а также на недостаточное использование и пренебрежение иранскими 
фармацевтическими производителями и экспортерами на российском рынке. В качестве послед-
ствий для политики авторы рекомендуют сделать фармацевтическую продукцию приоритетной 
для экспорта на российский рынок, что приведет к более эффективному использованию произ-
водственного потенциала Ирана. 
Ключевые слова: экспорт; фармацевтическая продукция; российский рынок; выявленные 
сравнительные преимущества; индекс косинуса; индекс торгового плана. 
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